|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.95 - 6.00|
|52 Week Range||5.95 - 6.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dimension Therapeutics Inc (NASDAQ:DMTX), a biotechnology company based in United States, led the NasdaqGS gainers with a relatively large price hike in the past couple of weeks. Less covered, small-stocksRead More...
The Cambridge, Massachusetts-based company said it had a loss of 68 cents per share. The gene therapy company posted revenue of $4.5 million in the period. Dimension Therapeutics shares have climbed 37 ...
NEW YORK , Oct. 24, 2017 /PRNewswire/ -- BroadSoft, Inc. (BSFT) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale of ...
BALA CYNWYD, PA / ACCESSWIRE / October 13, 2017 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Dimension Therapeutics, Inc. ("Dimension" ...
NEW YORK , Oct. 13, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dimension Therapeutics, Inc. ("DMTX" ...
NEW YORK, NY / ACCESSWIRE / October 12, 2017 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New ...
NEW YORK , Oct. 5, 2017 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of Dimension Therapeutics, Inc. ("Dimension" or the ...
After weighing buyout offers from two biotechs, gene therapy company Dimension Therapeutics said Tuesday that it accepted the superior proposal — a $151 million deal from a North Bay company that will allow the company to maintain a New England presence. Novato-based Ultragenyx Pharmaceutical (RARE) will buy Dimension (DMTX) for $6 per share. "I am thankful for the hard work and dedication of our talented employees, and am confident they will continue to make valuable contributions as part of a larger organization," Dimension CEO Annalisa Jenkins said in a statement.
After weighing buyout offers from two out-of-state biotechs, Cambridge gene therapy firm Dimension Therapeutics said Tuesday that it has accepted the superior proposal — a $151 million deal that will allow the company to maintain a local presence. Dimension (DMTX) said it had agreed to be acquired by California-based Ultragenyx Pharmaceutical (RARE) for $6 per share.
SAN DIEGO , Oct. 3, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dimension Therapeutics, Inc. (NASDAQ: DMTX) ("Dimension") ...
Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.
Rockville-based RegenxBio Inc. has opted to back away from a deal to buy Dimension Therapeutics Inc. (DMTX) after the Boston-area biotech received a better buyout offer. RegenxBio (RGNX) said Monday morning it doesn't plan to match, or best, the unsolicited $6-per-share price that Ultragenyx Pharmaceutical (RARE), based in Novato, California, is now offering to Dimension Therapeutics, a Cambridge, Massachusetts, biotech that's struggled with its pipeline in the last year. In August, RegenxBio announced plans to buy Dimension in an all-stock transaction that valued the deal at $3.41 per share, or $86 million in all.
NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Dimension Therapeutics and Clovis Oncology both saw big gains on Monday. It was takeover buzz that set Clovis shares moving north while Dimension soared ...
Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or the "Company" (ONCS)), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Annalisa Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc. (DMTX), to its Board of Directors. Dr. Jenkins brings over 25 years of global industry experience to OncoSec's Board of Directors with a wealth of knowledge in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally.